The significant unmet need that encompasses Acute Kidney Injury is that currently, neither there are any proven therapeutic strategies to reduce Acute Kidney Injury sequelae, nor affirmed robust evidence till date to inform strategy for the provision of healthcare.
The key players involved in developing promising therapeutic interventions to treat the Acute Kidney Injury includes: Alloksys Life Sciences BV, Angion, Quark Pharmaceuticals, AM-Pharma, Atox Bio, Exponential Biotherapies, Inc., MediBeacon Inc., Astellas Pharma US, and Pharming Technologies B.V.
The key emerging therapies in the Acute Kidney Injury pipeline will substantially provide a better outlook for the AKI treatment market to prosper and ultimately focus on addressing all the unmet needs surrounding the condition.
For more detailed information visit:
https://www.delveinsight.com/blog/acute-kidney-injury-pipeline/